Complain about a product or service

Scientists Raise Hopes For Alzheimer's Vaccine

June 22, 2007

• Low Levels of 'Good Cholesterol' Linked to Memory Loss, Dementia Risk • Chemical in Celery May Fight Alzheimer's • Dementia Linked To Obesity • Studies Find Link Between Diabetes and Alzheimer's • Lifestyle Linked to Alzheimer's Onset • Pot Belly in Middle Age Linked to Alzheimer's • 10 Million Boomers Face Alzheimer's • Alzheimer's Risk Higher in Victims' Children • Fast-Acting Alzheimer's Therapy Excites Researchers • Too Much Sugar May Increase Alzheimer’s Risk • Beta Carotene May Slow Memory Loss • Promising Alzheimer’s Discovery Reported • Misconceptions About Alzheimer's Vary Among Races • Mediterranean Diet May Extend Alzheimer’s Patients’ Lives • Researchers Link Smoking To Dementia • Caffeine May Keep Dementia At Bay In Women • Alzheimer’s Drug Seen As “Safe, Effective” • Researchers “A Step Closer” To Alzheimer’s Cure • FDA Approves Alzheimer’s Patch • Scientists Raise Hopes For Alzheimer's Vaccine • Researchers Hopeful About New Alzheimer’s Therapy • Blood Pressure Drugs May Provide Alzheimer’s Protection • Progress Toward Early Alzheimer's Diagnosis Reported • Alzheimer's Cases Up 10% In 5 Years • Loneliness Linked to Dementia • Gene Changes Identified in Alzheimer's • Mental Exercise May Help Seniors • Rote Learning Improves Memory in Seniors • Vegetables May Slow Memory Loss • Cabernet Sauvignon May Reduce Alzheimer's Risk • Fruit Juice May Reduce Alzheimer's Risk • Skin Test May Detect Alzheimer's Disease • Exercise May Prevent Dementia-Like Illnesses • An Apple A Day May Improve Memory • New Drug Reverses Alzheimer's Damage, Australian Researchers Report • Diabetes Drug May Help Treat Alzheimer's • For Women, Weight Loss May Precede Dementia • Researchers "Closer" To Preventing Alzheimer's • Statins Help Memory in Older Women • Study Links Healthy Diet To Reduced Alzheimer's Risk • Tea May Help Combat Alzheimer's • Education May Accelerate Alzheimer's Effects • Alzheimer's Found to be Mostly Genetic • Exercise May Reduce Risk of Dementia in Older People • Researchers Find DNA Link to Alzheimer's • Brain Scan, Fluid Analysis May Help Predict Alzheimer's • Eating Fish Associated With Slower Cognitive Decline • Word Recall An Alzheimer' s Tip-Off? • Interrupted Alzheimer's Trial Produced Promising Results • Gene Therapy May Offer Hope For Alzheimer's Patients • Alzheimer's Researchers Reverse Memory Loss in Mice • Alzheimer's Disease Reveals Itself Earlier, Study Finds

It's the Holy Grail of geriatric medicine – a vaccine against Alzheimer's disease. Now, scientists have provided new details about how proteins used to destroy bacteria and viruses may help treat this feared and heartbreaking disease.

Gunnar K. Gouras, associate professor of neurology and neuroscience at Weill Medical College of Cornell University, New York, and colleagues have been studying how these proteins, called antibodies, reduce the main hallmarks of Alzheimer’s disease and raise hopes for a vaccine against the disease.

“Antibodies are probably the most promising experimental approach to fight Alzheimer’s disease at this time,” Gouras said. “The discoveries made using antibodies are so encouraging that results of ongoing vaccine trials against the disease are much anticipated.”

Alzheimer’s disease, the most common form of dementia, gradually destroys a person's memory and ability to learn, communicate, and carry out daily activities.

According to the American Health Assistance Foundation, more than 4.5 million people in the United States live with the disease and more than 26 million people are affected worldwide. By 2050, the number of people who will suffer from the disease is estimated to nearly triple in the United States and to be four times as high worldwide.

Treatments Sought

Although no cure for the disease is available yet, scientists are actively looking for new treatments.

One of the main goals of such treatments is to destroy clumps of a protein called beta amyloid, which are found in the brains of people with the disease, either inside the nerve cells or around them. Antibodies have been shown to be effective at removing these clumps but how they do it is not completely understood.

In their new study, appearing as the cover story of the June 29 issue of the Journal of Biological Chemistry, Gouras and his colleagues provide new details about how the antibodies attack these clumps inside the nerve cells.

The study was selected as a “Paper of the Week” by the journal’s editor, meaning that it belongs to the top one percent of papers reviewed in significance and overall importance.

Using cultured cells from mice, the scientists showed that the antibodies first bind to the surface of the cells and connect to a protein called amyloid precursor protein (APP), which is already present on the cell surface. Then both proteins are internalized inside the cell.

Once inside the cell, APP is broken down into pieces, some of which are the amyloid beta proteins. If the antibodies are not present, the proteins start clustering and ultimately kill the cell.

The scientists showed that the antibodies prevent this from happening by reducing accumulation of the amyloid beta proteins in vesicles inside the cell called endosomes.

“A lot of research has been done on protein clusters outside nerve cells,” Gouras says. “In this study, we investigated for the first time what happens inside the cells and how antibodies can help prevent clusters from forming.”

Communication Restored

The researchers also found that the antibodies helped restore communication between nerve cells.

In Alzheimer’s patients, the protein clusters alter parts of the cell surfaces – the synapses – that help nerve cells talk to one another. As a result, thoughts are not transmitted, memory is lost, and new learning is hindered.

But Gouras and his team showed that the antibodies cleared the protein clusters and helped cells talk to one another again.

Over the past seven years, research results on the use of antibodies against Alzheimer’s disease have been so promising that two pharmaceutical companies, Ireland’s Elan Corp. and U.S. partner Wyeth, have been conducting clinical trials of a potential vaccine.

Although the first trials were stopped when 6 percent of the patients developed encephalitis – an inflammation of brain tissue – other clinical tests on the treated patients have been encouraging. In the second half of this year, the two companies will test a potential drug, called Bapineuzumab, on patients with mild to moderate Alzheimer’s symptoms.

If successful, researchers say these trials could result in a new type of vaccine containing antibodies that would directly attack the amyloid beta protein clusters.

Unlike common vaccines, which, in this case, would contain pieces of amyloid beta proteins and would stimulate the immune system to produce antibodies, the new vaccine would directly provide the antibodies to patients.

“These new developments are encouraging, but possible side effects may arise,” Gouras says. He adds that although clinical trials need to be conducted as soon as possible to help alleviate the suffering of the increasing number of Alzheimer’s patients, more research is still needed both to understand how amyloid beta proteins wreak havoc in the brain and to improve potential drugs.

Gouras and his colleagues are now trying to figure out how the protein clusters inside and outside the cells work together to destroy the cells.

They already noticed that the clusters outside the cells affect those inside cells by making them grow. Another challenge will be to better understand what the clusters do inside the cells that leads to their death. The scientists are also using imaging and biochemical techniques to see, in cultured cells, how the antibodies affect the clusters.

“We have many indications that antibodies work,” Gouras said. “Now we need to understand how they do it.”

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.